News
Every news piece, newest first.
Explore the latest erythropoietin research, focusing on new findings, potential applications, and what remains unknown about this hormone.
Discover what is reta peptide, its clinical data, side effects, and current research status in weight loss and diabetes management.
Retatrutide FDA approval status: not approved as of July 2026. It's in Phase 3 trials, with an NDA expected and approval projected for 2027 at earliest.
GLOW is an informal multi-peptide skin rejuvenation stack — typically GHK-Cu, BPC-157, and TB-500. Here's what it is, the mechanism rationale, and how it compares to topical-only approaches.
KLOW is an informal research-community stack combining KPV, Larazotide, Orexin-related compounds, and Wolverine-stack peptides for combined gut, inflammation, sleep, and tissue support.
Cagrilintide (AM833) is Novo Nordisk's long-acting amylin receptor agonist. Combined with Semaglutide it produces ~17–22% weight loss in Phase 3 trials with a different mechanism than GLP-1.
Retatrutide (LY3437943) is a GLP-1 + GIP + glucagon triple receptor agonist producing ~24% weight loss at 48 weeks in Phase 2 trials. Here's what it is, how it works, and where it stands.
SLU-PP-332 is a synthetic pan-ERR agonist that mimics endurance-exercise gene expression in animal models. Here's what's actually known, what's speculative, and why caution is warranted.